ArticleJournal of cellular and molecular medicine2021
Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth.
Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Activating a novel cell death pathway to target PI-resistant multiple myeloma and enhance immunogenic cell death.Apoptosis : an international journal on programmed cell death · 2026Article
- Article
- Anwulignan Alleviates Bone Cancer Pain by Modulating the PPARα/CXCR2 Signaling Pathway in the Rat Spinal Cord.CNS neuroscience & therapeutics · 2025Article
- Anwuligan promotes the transition of the hair follicle cycle via the Wnt/β-catenin signaling pathway.Frontiers in pharmacology · 2025Article
- A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.Annals of hematology · 2024Article
- Green SeaweedMarine drugs · 2024Article
- Anti-Cancer Effects of α-Cubebenoate Derived fromMolecules (Basel, Switzerland) · 2022Article
- Identification of Potent and Selective JAK1 Lead Compounds Through Ligand-Based Drug Design Approaches.Frontiers in pharmacology · 2022Article
- Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth.Journal of cellular and molecular medicine · 2021Article
- Pharmacological Effects of Polyphenol Phytochemicals on the JAK-STAT Signaling Pathway.Frontiers in pharmacology · 2021Review
- [Anwulignan inhibits malignant phenotypes of gastric cancer cells by antagonizing activation of the JAK1/STAT3 signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Anwulignan is a monomer compound derived from Schisandra sphenanthera lignans. It has been reported to possess a spectrum of pharmacological activities, including anti-bacterial, anti-inflammatory, anticancer and hepatoprotective properties. However, its anticancer capacity and molecular mechanism(s) against non-small cell lung cancer (NSCLC) have not been fully elucidated. Anwulignan significantly inhibited cell growth and increased G1-phase cell cycle arrest in NSCLC cells. Anwulignan strongly attenuates the JAK1/STAT3 signalling pathway by directly targeting JAK1 protein kinase activity in vitro. The anticancer activity by Anwulignan is dependent upon the JAK1 protein expression. Remarkably, Anwulignan strongly inhibited tumour growth in vivo. In conclusion, Anwulignan is a novel JAK1 inhibitor that may have therapeutic implications for NSCLC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.